GlassScriptPhysician profile
Gary J Foster
NPI 1730185182
$74,741.08
in general payments reported to CMS, 2019-2025
29 companies · $2,514 in 2025
The $2,514 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,936 · 2020: $696 · 2021: $7,893 · 2022: $11K · 2023: $26K · 2024: $24K · 2025: $2,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Food and Beverage: $4,735 · Travel and Lodging: $2,557 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,300 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,059.50 |
| Food and Beverage | $4,735.19 |
| Travel and Lodging | $2,557.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,300.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $60,886.50 | 2019-2025 | Lensx, Clareon, Acrysof Iq Vivity |
| Alcon Research LLC | $6,127.50 | 2023-2024 | |
| Rayner Intraocular Lenses Limited | $2,824.21 | 2022-2023 | Omidria |
| Eyevance Pharmaceuticals LLC | $1,455.20 | 2019 | |
| Glaukos Corporation | $600.22 | 2022-2025 | Idosetr, Ce-Marked Kxla System, Istent Trabecular Micro-Bypass System Model Is3 |
| Rxsight INC | $448.73 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| New World Medical,INC. | $423.05 | 2021-2025 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Bausch & Lomb Americas INC. | $275.43 | 2022-2023 | Miebo, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $202.32 | 2019-2024 | Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $199.70 | 2020-2025 | |
| Kala Pharmaceuticals, INC. | $164.94 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $164.47 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $148.34 | 2024 | Dextenza |
| Lensar, INC. | $114.61 | 2025 | Lensar Laser System |
| Sight Sciences, INC. | $112.08 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $87.56 | 2021 | |
| Abbvie INC. | $69.04 | 2023-2025 | |
| Allergan, INC. | $66.03 | 2019-2022 | |
| Ivantis, INC | $63.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $63.11 | 2020-2022 | |
| Carl Zeiss Meditec, INC. | $55.79 | 2019-2023 | Visumax |
| Mallinckrodt Hospital Products INC. | $50.27 | 2022 | |
| Omeros Corporation | $44.67 | 2019-2021 | |
| Dompe US, INC. | $24.82 | 2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $21.90 | 2019 | |
| Harrow Eye, LLC | $17.84 | 2025 | Iheezo |
| Thea Pharma INC. | $16.09 | 2023 | |
| Shire North American Group INC | $13.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.